Abstract

The Cancer Center has a vibrant and effective Clinical Protocol and Data Management infrastructure, composed of the following key elements: 1. An oversight committee, the Clinical Trials Advancement Committee (CTAC) 2. A central office, the Office for Clinical Research (OCR) 3. Disease-specific research teams 4. A Cancer Bioinformatics team 5. The Clinical Research Implementation Committee (CRIC) 6. Ancillary services including the Investigational Drug Services Pharmacy (IDS Pharmacy), Emily Couric Clinical Cancer Center (ECCCC) Nurse Liaison, and Biorepository and Tissue Research Facility (BTRF) 7. Cancer Center Clinical Research Orientation, Training, and Quality Assurance Program 8. Data and Safety Monitoring Plan (DSMP) and Data and Safety Monitoring Committee (DSMC) 9. Minority Recruitment Task Force (MRTF) Over the past five years, the Cancer Center has almost doubled accrual to therapeutic trials. The significant increase in accruals to treatment trials reflects the successful expansion and optimization of the clinical research infrastructure.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-28
Application #
9626882
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
28
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904

  Publications

Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679

Showing the most recent 10 out of 539 publications